CME

CME

By ReachMDMedicine
Download on the App Store

CME episodes

  • ACC 2024: SHASTA-2 Final Study Results
    Host: Daniel Gaudet, MD, PhD

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

    6 min
  • Plozasiran (ARO-APOC3) Decreases APOC3 and Triglycerides (TG) in Patients With Mixed Hyperlipidemia: MUIR Final Results
    Host: Christie Ballantyne, MD

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

    5 min
  • ACC 2024: The PIONEER AF-PCI Trial
    Host: Manesh R. Patel, MD

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

    5 min
  • ACC 2024: What's Really New in Electrophysiology That Will Change My Practice?
    Host: Manesh R. Patel, MD

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

    6 min
  • ACC 2024: VOYAGER PAD Part 1
    Host: Marc P. Bonaca, MD, MPH

    This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions and the 92nd European Atherosclerosis Society (EAS) Congress. From clinical trials like PIONEER-AF, VOYAGER PAD, SHASTA 2 and MUIR to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

    6 min
  • Glycine's Role in Driving the Cognitive Symptoms of CIAS
    Host: Philip D. Harvey, PhD
    Guest: Martin Strassnig, MD

    This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

    5 min
  • Tools of the Trade: Measurement-Based Care for CIAS
    Host: Martin Strassnig, MD
    Guest: Philip D. Harvey, PhD

    This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

    6 min
  • Limitations of the Current Therapeutics Used to Manage CIAS
    Host: Philip D. Harvey, PhD
    Guest: Martin Strassnig, MD

    This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

    6 min